Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.
Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.
复制标题
DOI：
10.1080/08897077.2020.1809603
复制
发表时间：
2021
期刊：
影响因子：
3.5
通讯作者：
Friedmann, Peter D.
中科院分区：
文献类型：
--
作者：
Pivovarova, Ekaterina;Min, Hye Sung;Friedmann, Peter D.
关键词：
了解治疗阿片类药物使用障碍的药物对健康相关生活质量 (QOL) 的影响可能有助于解释为什么很少有合法参与的人，特别是那些接受阿片类拮抗剂的人继续接受治疗。生活质量是治疗保留的既定预测指标，并且已被证明可以通过某些阿片类药物使用障碍的治疗来改善。然而，对阿片类拮抗剂的生活质量进行检验的研究还很有限。我们在一项针对有法律参与的个人的随机、多中心试验中研究了缓释纳曲酮 (XR-NTX) 对生活质量和治疗保留的影响。参与者是 308 名居住在社区的成年人，他们目前或最近在美国五个地点因阿片类药物依赖而陷入法律困境。他们被随机接受 XR-NTX 或照常治疗 6 个月。每两周使用欧洲生活质量单项、总结指数得分和今日健康状况指标测量生活质量。在完成积极治疗或 52 周和 78 周随访时，两组之间的 QOL 评分没有显着差异。治疗对分数没有时间影响。与预期相反，基线和平均生活质量并不能预测治疗的保留。与之前的研究相比，我们的研究结果并未表明与 XR-NTX 治疗相关的生活质量发生显着变化（改善或下降）。临床医生可能会认为接受 XR-NTX 的个体可能不会因治疗而出现感知健康的变化，并考虑与患者讨论他们可能不一定会感知到生活质量的改善。这可能有助于奠定患者对治疗效果的期望，并可能减少阿片类拮抗剂治疗的损耗。
Understanding the impact of medications for opioid use disorder on health related quality of life (QOL) may help to explain why few individuals with legal involvement remain in treatment, specifically those receiving opioid antagonists. QOL is an established predictor of treatment retention and has been shown to improve with some treatment for opioid use disorder. Yet limited research has examined QOL with opioid antagonists. We examined the impact of extended release naltrexone (XR-NTX) on QOL and retention in treatment in a randomized, multi-site trial of individuals with legal involvement. The participants were 308 community-dwelling adults with current or recent legal involvement with opioid dependence at five site across United States. They were randomized to receive XR-NTX or treatment as usual for 6 months. QOL was measured every 2 weeks using Euro QOL individual items, summary index score, and health state today metric. No significant difference in QOL scores were observed between the two groups at the completion of active treatment or on follow up at 52 and 78 weeks. There were no time effects of treatment on scores. Contrary to expectation, baseline and average QOL did not predict retention in treatment. In contrast to prior research, our findings did not demonstrate significant changes (improvements or decreases) in QOL associated with XR-NTX treatment. Clinicians may consider that individuals receiving XR-NTX may not experience changes in perceived well-being in response to treatment and consider discussing with patients that they may not necessarily perceive improvement in their QOL. This may help to ground patient’s expectations about the effects of treatment and potentially reduce attrition from treatment with opioid antagonists.
登录
查看更多内容
影响因子：
3.5
作者：
Friedmann PD;Hoskinson R;Gordon M;Schwartz R;Kinlock T;Knight K;Flynn PM;Welsh WN;Stein LA;Sacks S;O'Connell DJ;Knudsen HK;Shafer MS;Hall E;Frisman LK;Mat Working Group Of CJ-Dats
通讯作者：
Mat Working Group Of CJ-Dats
影响因子：
120.7
作者：
Chandler, Redonna K.;Fletcher, Bennett W.;Volkow, Nora D.
通讯作者：
Volkow, Nora D.
影响因子：
10.3
作者：
Land, Stephanie R.;Walcott, Farzana L.;Ganz, Patricia A.
通讯作者：
Ganz, Patricia A.
影响因子：
3.5
作者：
Herdman, M.;Gudex, C.;Lloyd, A.;Janssen, M. F.;Kind, P.;Parkin, D.;Bonsel, G.;Badia, X.
通讯作者：
Badia, X.
影响因子：
2
作者：
Laudet, Alexandre B.;Becker, Jeffrey B.;White, William L.
通讯作者：
White, William L.